研報掘金丨信達證券:百龍創園Q2業績再創新高,維持“買入”評級
信達證券研報指出,百龍創園2025H1實現歸母淨利潤1.71億元,同比+42.68%;其中,25Q2實現歸母淨利潤8917萬元,同比+35.07%。公司收入利潤持續增長,其中第二季度收入和利潤均創單季度歷史新高,歸母淨利潤率達26.54%,同樣創歷史新高。市場需求的旺盛帶動公司新產能的持續釋放,使得公司今年以來業績表現持續優異。同時,近期阿洛酮糖的獲批有望爲公司帶來新的收入增量,而泰國基地的建設也有望進一步驅動公司中期業績增長。上調盈利預測,預計公司2025-2027年EPS爲0.84/1.09/1.42元,分別對應2025-2027年26X/20X/15XPE,維持對公司的“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.